Adapted from Warren et al. 2020
Data from IMMerge, a phase III, global, multicentre, randomised, open-label, efficacy assessor-blinded active-comparator study in adult patients with moderate to severe plaque psoriasis.
NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index. P-values for comparison vs secukinumab: *P<0.001 multiplicity controlled.
Data assessed for intent-to-treat population. Adjusted difference CI set at 95%; P values calculated from the Cochran-Mantel-Haenszel test, stratified by weight (≤100 kg vs >100 kg) and prior systemic biologic use for psoriasis.
†Each dose for SKYRIZI given as two 75-mg subcutaneous injections, each dose for secukinumab given as two 150-mg subcutaneous injections.
All ranked secondary endpoints were met, including statistically significant superiority of SKYRIZI vs secukinumab at Week 52 (PASI 100: 66% vs 40%, P<0.001). Co-primary endpoints were met: PASI 90 at Week 16 (non-inferiority) and PASI 90 at Week 52 (superiority)